poisar

Stock

Whitehawk Therapeutics, Inc. WHWK

$3.85+0.00%

Overview

WHWK market data

Price History

WHWK price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.44
Diluted earnings per share over the trailing twelve months.
Beta
0.82
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.57 – $5.50
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $212.5 · P/B 0.84 · P/S 7.65.

Company News

6 captured
Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9Benzinga · Jul 13, 2026, 5:55 PM
Whitehawk Therapeutics Collaborates With Biocytogen To Develop Bispecific Antibody-Drug ConjugatesBenzinga · Jul 7, 2026, 12:10 PM
Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common StockBenzinga · May 29, 2026, 8:25 PM
8-K filing — Whitehawk Therapeutics, Inc. (WHWK)SEC EDGAR · May 21, 2026, 9:16 PM
Whitehawk Therapeutics Enters Into A New Option Agreement With Hangzhou DAC For Access To CPT113 For Use In Up To Five Additional ADC Programs; Phase 1 Dose-Escalation Trials Of HWK-007 And HWK-016 Are Currently Enrolling; HWK-007 Trials-In-Progress Poster To Be Presented At ASCOBenzinga · May 21, 2026, 9:15 PM
Whitehawk Therapeutics Enters PIPE Financing With Expected Gross Proceeds Of ~$87.5M From Sale Of 4,330,866 Shares At $3.92 Per Share And Warrants To Purchase 17,991,021 Shares At $3.9199 Per WarrantBenzinga · May 13, 2026, 12:12 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock
Whitehawk Therapeutics, Inc. (WHWK) stock — price, valuation & news | Poisar